TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

20 فبراير 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

31 يناير 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

11 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

09 نوفمبر 2023 16:05:01 بحسب Nasdaq GlobeNewswire

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

01 نوفمبر 2023 18:35:08 بحسب Nasdaq GlobeNewswire

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

06 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

30 أغسطس 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

24 أغسطس 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

10 أغسطس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

01 أغسطس 2023 22:30:33 بحسب Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

31 يوليو 2023 16:29:44 بحسب Nasdaq GlobeNewswire

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

12 يونيو 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

05 يونيو 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

09 مايو 2023 16:05:02 بحسب Nasdaq GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

08 مايو 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

03 مايو 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

24 أبريل 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

13 مارس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

02 مارس 2023 16:30:00 بحسب Nasdaq GlobeNewswire